comparemela.com

Latest Breaking News On - Kaitlin gallagher - Page 2 : comparemela.com

Liminal BioSciences Reports Fourth Quarter and Year Ended 2022 Financial Results

CTA-enabling work on track to seek approval to commence Phase 1 clinical trial of LMNL6511 during the second half of 2023 Addition of GPR40 agonist discovery.

Cambridge
Cambridgeshire
United-kingdom
Canada
Quebec
Pointe-claire
Canadian
Kaitlin-gallagher
Bruce-pritchard
Nicole-rusaw
Shrinal-inamdar
Exchange-commission

vimarsana © 2020. All Rights Reserved.